Archford Capital Strategies’s Teva Pharmaceuticals TEVA Stock Holding History

Archford Capital Strategies’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-69	Closed	-$2K	–	576
2017 Q1	$2K	Hold	69	–	–	﹤0.01%	612
2016 Q4	$2K	Buy	69 +7	+11%	+$279	﹤0.01%	537
2016 Q3	$2K	Sell	62 -62	-50%	-$3.23K	﹤0.01%	552
2016 Q2	$6K	Buy	+124	New	+$6.6K	﹤0.01%	469
2016 Q1	–	Sell	-619	Closed	-$42K	–	551
2015 Q4	$42K	Buy	619 +66	+12%	+$4.08K	0.02%	277
2015 Q3	$32K	Sell	553 -56	-9%	-$3.63K	0.02%	222
2015 Q2	$36K	Buy	609 +148	+32%	+$9.13K	0.03%	219
2015 Q1	$28.7K	Hold	461	–	–	0.02%	252
2014 Q4	$27K	Buy	461 +398	+632%	+$22.2K	0.02%	263
2014 Q3	$3K	Hold	63	–	–	﹤0.01%	462
2014 Q2	$3.3K	Buy	63 +10	+19%	+$511	﹤0.01%	567
2014 Q1	$2.8K	Buy	+53	New	+$2.45K	﹤0.01%	600

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Archford Capital Strategies's TEVA Position: Q2 2017 in Review

Archford Capital Strategies sold out of Teva Pharmaceuticals (TEVA) in Q2 2017, closing a stake of 69 shares — an estimated $2K sold.

Archford Capital Strategies first reported a position in TEVA in Q1 2014 and held it in 12 quarters. The position peaked at $42K in Q4 2015. 649 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

Archford Capital Strategies reported no remaining Teva Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Archford Capital Strategies sold 69 Teva Pharmaceuticals shares in Q2 2017, an estimated $2K.
Archford Capital Strategies first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 12 quarters.
Archford Capital Strategies's Teva Pharmaceuticals position peaked at $42K in Q4 2015.
649 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on Archford Capital Strategies's 13F filing for Q2 2017, filed 18 Aug 2017.